Forward agenda is conversion work: management's own stated priorities are about turning already-secured growth into resu
The model's full reasoning — Q3 2018 call → NOWe need answer YES/NO. Need analyze transcript. Need determine if forward agenda is conversion work and secured growth still ahead of numbers. Company Agios. Q3 2018. TIBSOVO launched July 2018, first partial quarter sales $4.5M. Management describes launch progress, future milestones. Need see if forward agenda substantially about converting growth already secured into delivered results, and reported results don't yet reflect secured growth. Let's parse. David opening: "third quarter exciting... achievement clinical regulatory milestones... put us on track to complete remaining milestones... began to lay groundwork to support next phase of growth in 2019 and beyond, focused on expanding indications for wholly-owned precision medicine TIBSOVO, rapidly advancing both cancer and rare genetic disease clinical development programs and continuing to foster rich research pipeline." This is broad. "Notably, July approval and launch of TIBSOVO... We're pleased with progress of U.S. launch." Then IDHIFA award. "For TIBSOVO, we know that our work has just begun to provide access to more patients with an IDH mutation. Today, we announced two key updates to ambitious clinical development strategy in newly diagnosed AML. Most importantly, we plan to submit supplemental NDA for single agent TIBSOVO in AML patients not eligible for standard therapies." This is regulatory submission, not conversion of existing sales. "Turning to solid tumors. In September, Agios gained worldwide rights to AG-881... We now have global rights for two IDH1 mutant inhibitors for potential treatment of low-grade glioma... Beyond IDH, team conducting patient identification and disease education work to help enroll Mitapivat Pivotal Trials in PK deficiency, which we expect to complete enrollment in 2019. We are also exploring role of pyruvate kinase activation in other anemias and remain on track to start Phase 2 proof-of-concept study in thalassemia by end of year. Early oncology pipeline continues to advance AG-270 through dose-escalation. In addition, we have submitted IND for AG-636... As we head into year-end, focused on upcoming ASH meeting, presenting clinical updates." This is mostly pipeline development, regulatory submissions, clinical trials.
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| ERO | Ero Copper Corp. | Q1 2024 | 2024-05-10 | A |
| AZEK | The AZEK Company Inc. | Q2 2024 | 2024-05-08 | B+ |
| AES | The AES Corporation | Q1 2024 | 2024-05-03 | C+ |
| ROCK | Gibraltar Industries, Inc. | Q1 2024 | 2024-05-01 | B+ |
| DUOT | Duos Technologies Group, Inc. | Q4 2023 | 2024-04-01 | F |
| KOPN | Kopin Corporation | Q4 2023 | 2024-03-14 | C+ |
| GIII | G-III Apparel Group, Ltd. | Q4 2024 | 2024-03-14 | C |
| BRBR | BellRing Brands, Inc. | Q4 2023 | 2023-11-21 | B+ |
| EFXT | Enerflex Ltd. | Q3 2023 | 2023-11-09 | C+ |
| PTLO | Portillo's Inc. | Q2 2023 | 2023-08-05 | B |
| GVP | GSE Systems, Inc. | Q1 2023 | 2023-05-15 | D |
| CDE | Coeur Mining, Inc. | Q1 2023 | 2023-05-11 | C+ |
| KE | Kimball Electronics, Inc. | Q3 2023 | 2023-05-06 | C+ |
| BRX | Brixmor Property Group Inc. | Q1 2023 | 2023-05-02 | A |
| TACT | TransAct Technologies Incorporated | Q4 2022 | 2023-03-08 | A |
| ESEA | Euroseas Ltd. | Q4 2022 | 2023-02-15 | C+ |
| PI | Impinj, Inc. | Q4 2022 | 2023-02-08 | B+ |
| CEIX | CONSOL Energy Inc. | Q4 2022 | 2023-02-07 | B |
| PKOH | Park-Ohio Holdings Corp. | Q3 2022 | 2022-11-13 | B |
| FLL | Full House Resorts, Inc. | Q3 2022 | 2022-11-07 | B |
| MEC | Mayville Engineering Company, Inc. | Q3 2022 | 2022-11-05 | B+ |
| EVGO | EVgo, Inc. | Q2 2022 | 2022-08-09 | C+ |
| CRL | Charles River Laboratories International | Q2 2022 | 2022-08-03 | C |
| SYM | Symbotic Inc. | Q3 2022 | 2022-08-01 | B+ |
| OGI | OrganiGram Holdings Inc. | Q3 2022 | 2022-07-14 | B+ |
| VNRX | VolitionRx Limited | Q1 2022 | 2022-05-12 | F |
| BXP | Boston Properties, Inc. | Q1 2022 | 2022-05-03 | A |
| FAT | FAT Brands Inc. | Q4 2021 | 2022-03-21 | F |
| FLUX | Flux Power Holdings, Inc. | Q2 2022 | 2022-02-10 | D |
| GTES | Gates Industrial Corporation plc | Q4 2021 | 2022-02-07 | C+ |
| GFS | GLOBALFOUNDRIES Inc. | Q3 2021 | 2021-11-30 | A |
| RNW | ReNew Energy Global Plc | Q2 2022 | 2021-11-18 | C |
| BFI | BurgerFi International, Inc. | Q3 2021 | 2021-11-12 | C |
| HY | Hyster-Yale Materials Handling, Inc. | Q3 2021 | 2021-11-06 | D |
| OWL | Blue Owl Capital Inc. | Q2 2021 | 2021-08-10 | B+ |
| ALB | Albemarle Corporation | Q3 2018 | 2018-11-08 | B |
| KOP | Koppers Holdings Inc. | Q2 2018 | 2018-08-12 | C+ |
| PRIM | Primoris Services Corporation | Q2 2018 | 2018-08-11 | C+ |
| XOM | Exxon Mobil Corporation | Q2 2018 | 2018-07-27 | C |
| KIM | Kimco Realty Corporation | Q2 2018 | 2018-07-26 | B+ |
| MKC | McCormick & Company, Incorporated | Q2 2018 | 2018-06-28 | C+ |
| ACHC | Acadia Healthcare Company, Inc. | Q4 2017 | 2018-02-22 | C+ |
| SBSI | Southside Bancshares, Inc. | Q4 2017 | 2018-02-06 | A |
| CPK | Chesapeake Utilities Corporation | Q3 2017 | 2017-11-10 | A |
| GNTX | Gentex Corporation | Q3 2017 | 2017-10-20 | B |
| LIND | Lindblad Expeditions Holdings, Inc. | Q2 2017 | 2017-08-06 | C |
| FLEX | Flex Ltd. | Q1 2018 | 2017-07-28 | F |
| BP | BP p.l.c. | Q4 2016 | 2017-02-07 | B+ |
| ARAY | Accuray Incorporated | Q4 2016 | 2016-08-17 | B |
| GOGO | Gogo Inc. | Q1 2016 | 2016-05-06 | C+ |
| ESE | ESCO Technologies Inc. | Q2 2016 | 2016-05-03 | A |
| RCL | Royal Caribbean Cruises Ltd. | Q1 2016 | 2016-04-29 | C+ |
| HPP | Hudson Pacific Properties, Inc. | Q4 2015 | 2016-02-25 | C |
| HXL | Hexcel Corporation | Q4 2015 | 2016-01-22 | B+ |
EVGO · Q2 2022 → YESThe question is about whether management's forward agenda is about converting already secured growth into results, and if the reported results don't yet reflect that growth. YES The forward agenda centers on converting already-secured growth: the Pilot-GM eXtend deal (up to 2,000 stalls + 500 locations) is described as recently announced and exceeding IRR hurdles, with EVgo procuring, constructing, operating, and maintaining the assets on a capital-light basis; the 2022 guidance is affirmed and tracked, with heavier second-half loads explicitly tied to PFJ and fleet contractual revenues kicking in Q3/Q4 (some already baked into forecasts after late-2021 negotiations); current stall counts (2,397 in operation/under construction, 3,669 pipeline) and throughput explicitly exclude the 2,000-stall Pilot contribution; Delta supply agreement covers the first phase of the PFJ deal through 2026; and execution themes include ramping stalls, commissioning, fleet onboarding, and regulatory credit recognition tied to these committed contracts. The reported Q2 results ($9.1M revenue, 10.
BRBR · Q4 2023 → YESThe question is: On this call, when management describes what the company is focused on over the coming quarters — its own stated priorities, tasks, and to-do list — is that forward agenda substantial...YES The forward agenda centers on converting already-secured growth by ramping production (17% growth in fiscal '23, 20%+ planned for '24 via new co-mans and Michael Foods startup in December), restarting promotions and marketing once supply allows, and scaling the transformed co-man network to fulfill committed demand — all while noting tight supply dynamics persisting through most of fiscal '24. Management explicitly conveys that the reported FY '23 results (22% sales growth, 25% EBITDA growth) reflect only a portion of the secured trajectory, with the bulk of new capacity contributions and promotional lift still ahead in fiscal '24, treating 10-15% sales and 6-15% EBITDA guidance as the meaningful next step rather than a routine continuation.
EFXT · Q3 2023 → YESThe question is: Does management describe their focus over coming quarters as converting already secured growth into delivered results, AND do they convey that reported results don't yet meaningfully ...YES The transcript shows management's forward agenda centers on converting secured growth: executing on the $1.6 billion Engineered Systems backlog for 2024 revenue visibility, realizing remaining USD 60 million synergies from Exterran integration, consolidating facilities, and prioritizing debt reduction plus operational efficiency. They describe this as turning already-committed 2024 activity into delivered results, with the backlog providing "strong visibility into revenue generation and business activity levels for 2024" and embedded margins in line with mid-teens targets.